Last reviewed · How we verify
NCT03392480
Association of Haptoglobin 2-2 With Postoperative Delirium
trial in Postoperative Delirium. Withdrawn.
30 December 2019
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 20 December 2017 |
| Primary completion | 30 December 2019 |
| Estimated completion | 30 December 2019 |
| Sites | 8 locations across China |
Conditions studied
- Postoperative Delirium — all drugs for Postoperative Delirium →
Sponsor
Sun Yat-sen University
Who can join
45 and older, any sex, with Postoperative Delirium. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with major orthopedic surgery will be recruited. Participants will be monitored for delirium after surgery. Participants' blood will be harvested for the determination of haptoglobin types, levels of oxidative stress and inflammation. Investigators will then analyze the data to see if haptoglobin 2-2 type is associated with an increased postoperative delirium, inflammation and oxidative stress.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03392480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postoperative Delirium
Currently open trials in the same condition.
- NCT07323485 — Inflammatory Biomarkers and Postoperative Delirium in Pediatric Circumcision · recruiting
- NCT07411794 — Dexmedetomidine vs Midazolam in Coronary Artery By-pass Surgery · NA · recruiting
- NCT07239648 — Postoperative Delirium in Patients Undergoing Cardiac Surgery · recruiting
- NCT07217912 — Daridorexant to Prevent Post-cardiotomy Delirium · Phase 2 · recruiting
- NCT07108764 — Intraoperative Infusion of Either Lidocaine or Dexmedetomidine on Regional Cerebral Oxygen Saturation and Postoperative · NA · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03392480 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 23 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03392480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing